69 related articles for article (PubMed ID: 10528911)
1. Future strategies toward the cure of indolent B-cell malignancies. New biologic therapies.
Rai KR
Semin Hematol; 1999 Oct; 36(4 Suppl 5):12-7. PubMed ID: 10528911
[TBL] [Abstract][Full Text] [Related]
2. Future strategies toward the cure of indolent B-cell malignancies. Immune recognition and antiself.
Nadler LM
Semin Hematol; 1999 Oct; 36(4 Suppl 5):9-11. PubMed ID: 10528910
[TBL] [Abstract][Full Text] [Related]
3. Future strategies toward the cure of indolent B-cell malignancies. Molecular genetic approaches.
Kipps TJ
Semin Hematol; 1999 Oct; 36(4 Suppl 5):3-8. PubMed ID: 10528909
[TBL] [Abstract][Full Text] [Related]
4. Future strategies toward the cure of indolent B-cell malignancies: introduction.
Cheson BD
Semin Hematol; 1999 Oct; 36(4 Suppl 5):1-2. PubMed ID: 10528908
[No Abstract] [Full Text] [Related]
5. Phase I study of bryostatin 1 and fludarabine in patients with chronic lymphocytic leukemia and indolent (non-Hodgkin's) lymphoma.
Roberts JD; Smith MR; Feldman EJ; Cragg L; Millenson MM; Roboz GJ; Honeycutt C; Thune R; Padavic-Shaller K; Carter WH; Ramakrishnan V; Murgo AJ; Grant S
Clin Cancer Res; 2006 Oct; 12(19):5809-16. PubMed ID: 17020988
[TBL] [Abstract][Full Text] [Related]
6. Rituximab in B-cell disorders other than non-Hodgkin's lymphoma.
Bosly A; Keating MJ; Stasi R; Bradstock K
Anticancer Drugs; 2002 Nov; 13 Suppl 2():S25-33. PubMed ID: 12710588
[TBL] [Abstract][Full Text] [Related]
7. Potentiation of fludarabine cytotoxicity on non-Hodgkin's lymphoma by pentoxifylline and rituximab.
Alas S; Bonavida B; Emmanouilides C
Anticancer Res; 2000; 20(5A):2961-6. PubMed ID: 11062708
[TBL] [Abstract][Full Text] [Related]
8. Monoclonal antibody therapy of chronic lymphocytic leukemia.
Mavromatis B; Cheson BD
J Clin Oncol; 2003 May; 21(9):1874-81. PubMed ID: 12721266
[TBL] [Abstract][Full Text] [Related]
9. New chemotherapeutics strategies for the treatment of indolent lymphoid malignancies.
Cheson BD
Semin Hematol; 1999 Oct; 36(4 Suppl 5):26-33. PubMed ID: 10528913
[TBL] [Abstract][Full Text] [Related]
10. Novel and engineered anti-B-cell monoclonal antibodies for non-Hodgkin's lymphoma.
Martin P; Furman RR; Ruan J; Elstrom R; Barrientos J; Niesvizky R; Coleman M; Leonard JP
Semin Hematol; 2008 Apr; 45(2):126-32. PubMed ID: 18381108
[TBL] [Abstract][Full Text] [Related]
11. Stem-cell transplantation for indolent lymphoma.
Gribben JG
Semin Hematol; 1999 Oct; 36(4 Suppl 5):18-25. PubMed ID: 10528912
[TBL] [Abstract][Full Text] [Related]
12. lenalidomide enhances natural killer cell and monocyte-mediated antibody-dependent cellular cytotoxicity of rituximab-treated CD20+ tumor cells.
Wu L; Adams M; Carter T; Chen R; Muller G; Stirling D; Schafer P; Bartlett JB
Clin Cancer Res; 2008 Jul; 14(14):4650-7. PubMed ID: 18628480
[TBL] [Abstract][Full Text] [Related]
13. Immunogenetic therapy for B-cell malignancies.
Kipps TJ; Chu P; Wierda WG
Semin Oncol; 2000 Dec; 27(6 Suppl 12):104-9. PubMed ID: 11225994
[TBL] [Abstract][Full Text] [Related]
14. Newer monoclonal antibodies for hematological malignancies.
Castillo J; Winer E; Quesenberry P
Exp Hematol; 2008 Jul; 36(7):755-68. PubMed ID: 18565392
[TBL] [Abstract][Full Text] [Related]
15. Chronic lymphocytic leukemia.
Keating MJ
Semin Oncol; 1999 Oct; 26(5 Suppl 14):107-14. PubMed ID: 10561025
[TBL] [Abstract][Full Text] [Related]
16. Antibody-based therapeutics in oncology.
Ross J; Gray K; Schenkein D; Greene B; Gray GS; Shulok J; Worland PJ; Celniker A; Rolfe M
Expert Rev Anticancer Ther; 2003 Feb; 3(1):107-21. PubMed ID: 12597355
[TBL] [Abstract][Full Text] [Related]
17. Lymphoplasmacytic lymphoma/immunocytoma: towards a disease-targeted treatment?
Clavio M; Quintino S; Venturino C; Ballerini F; Varaldo R; Gatto S; Galbusera V; Garrone A; Grasso R; Canepa L; Miglino M; Pierri I; Gobbi M
J Exp Clin Cancer Res; 2001 Sep; 20(3):351-8. PubMed ID: 11718214
[TBL] [Abstract][Full Text] [Related]
18. Combination epigenetic and immunotherapy overcomes resistance to monoclonal antibodies in hematologic malignancies: A new therapeutic approach.
Epner EM; Saroya BS; Hasanali ZS; Loughran TP
Exp Hematol; 2016 Mar; 44(3):157-60. PubMed ID: 26802532
[TBL] [Abstract][Full Text] [Related]
19. Anti-PD-1-targeted therapies focusing on lymphatic malignancies: biological rationale, clinical challenges and opportunities.
Kedmi M; Avigdor A; Nagler A
Acta Haematol; 2015; 133(2):129-35. PubMed ID: 25247668
[TBL] [Abstract][Full Text] [Related]
20. Vaccine therapy of B cell malignancies: different strategies for a novel approach.
Liso A; Benedetti R; Flenghi L; Falini B
Leuk Lymphoma; 2001; 42(5):881-9. PubMed ID: 11697643
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
